High HIV burden among people who inject drugs in 15 Indian cities

AIDS

Volumn 29, Issue 5, 2015, Pages 619-628

  Lucas, Gregory M ^a   Solomon, Sunil S ^a,b   Srikrishnan, Aylur K ^b   Agrawal, Alok ^c   Iqbal, Syed ^b   Laeyendecker, Oliver ^a,d   McFall, Allison M ^e   Kumar, Muniratnam S ^b   Ogburn, Elizabeth L ^e   Celentano, David D ^e   Solomon, Suniti ^b   Mehta, Shruti H ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

harm reduction; HIV incidence; HIV prevalence; India; injecting drug use; needle and syringe exchange

Indexed keywords

ANXIOLYTIC AGENT; BUPRENORPHINE; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; OPIATE; SEDATIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HEALTH SURVEY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INDIA; INJECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VIRUS LOAD; CITY; COMPLICATION; CROSS-SECTIONAL STUDY; HIV INFECTIONS; INCIDENCE; INTERVIEW; PATHOLOGY; PREVALENCE; RISK ASSESSMENT; SUBSTANCE ABUSE;

ADULT; CITIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; INTERVIEWS AS TOPIC; MALE; PREVALENCE; RISK ASSESSMENT; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84926430756     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000592     Document Type: Article

References (29)

1. National AIDS Control Organisation, Department of AIDS Control, Ministry of Health & Family Welfare, Government of India. Annual Report 2012-13. 2013. http://www.naco.gov.in.
2. Chandrasekaran P, Dallabetta G, Loo V, Rao S, Gayle H, Alexander A. Containing HIV/AIDS in India: the unfinished agenda. Lancet Infect Dis 2006; 6:508-521.
3. Arora P, Kumar R, Bhattacharya M, Nagelkerke NJ, Jha P. Trends in HIV incidence in India from 2000 to 2007. Lancet 2008; 372:289-290.
4. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372:1733-1745.
5. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect 2006; 82 (Suppl 3):iii10-iii17.
6. Dorabjee J, Samson L. A multicentre rapid assessment of injecting drug use in India. Int J Drug Policy 2000; 11:99-112.
7. Medhi GK, Mahanta J, Akoijam BS, Adhikary R. Size estimation of injecting drug users (IDU) using multiplier method in five districts of India. Subst Abuse Treat Prev Policy 2012; 7:9.
8. Ambekar A, Tripathi BM. Size estimation of injecting drug use in Punjab and Haryana. UNAIDS; 2008. http://saathii.org/saathi iorc/index.php?option=com-docman&task=doc-download& gid=175&Itemid=5.
9. Yardley J. Indian state finds itself in tight grip of addiction. The New York Times, New York; 2012. http://www.nytimes.com/2012/04/19/world/asia/drug-addiction-is-a-growing-problemin-punjab.html?pagewanted=all&-r=0 (accessed 6/24/2014).
10. Mahanta J, Borkakoty B, Das HK, Chelleng PK. The risk of HIV and HCV infections among injection drug users in northeast India. AIDS Care 2009; 21:1420-1424.
11. Mahanta J, Medhi GK, Paranjape RS, Roy N, Kohli A, Akoijam BS, et al. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008; 22 (Suppl 5):S59-S68.
12. Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008; 49:327-332.
13. Baveja UK, Chattopadhya D, Khera R, Joshi PM. A cross sectional serological study of the co-infection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus amongst a cohort of IDUs at Delhi. Indian J Med Microbiol 2003; 21:280-283.
14. Abdul-Quader AS, Heckathorn DD, McKnight C, Bramson H, Nemeth C, Sabin K, et al. Effectiveness of respondent-driven sampling for recruiting drug users in New York City: findings from a pilot study. J Urban Health 2006; 83:459-476.
15. Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Social Problems 2002; 49:11-34.
16. Solomon SS, Lucas GM, Celentano DD, Sifakis F, Mehta SH. Beyond surveillance: a role for respondent-driven sampling in implementation science. Am J Epidemiol 2013; 178:260-267.
17. Saunders JB, Aasland OG, Babor TF, de lF Jr, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption: II. Addiction 1993; 88:791-804.
18. Laeyendecker O, Kulich M, Donnell D, Komarek A, Omelka M, Mullis CE, et al. Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One 2013; 8:e78818.
19. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-689.
20. Volz E, Heckathorn DD. Probability based estimation theory for respondent driven sampling. J Off Stat 2008; 24:79-97.
21. Salganik MJ, Heckathorn DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Methodol 2004; 34:193-239.
22. Delhi, Mumbai at the top of the list of Indian cities active in drug trade. Times of India; 2014. http://timesofindia.indiatimes.com/india/drug-trade/articleshow/37028283.cms?intenttarget=nos. [Accessed 22 July 2014]
23. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010; 376:551-563.
24. Panda S, Kumar MS, Lokabiraman S, Jayashree K, Satagopan MC, Solomon S, et al. Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr 2005; 39:9-15.
25. Solomon SS, Mehta SH, Latimore A, Srikrishnan AK, Celentano DD. The impact of HIV and high-risk behaviours on the wives of married men who have sex with men and injection drug users: implications for HIV prevention. J Int AIDS Soc 2010; 13 (Suppl 2):S7.
26. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis 2015; 15:36-45.
27. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010; 31:98-132.
28. Mehta SH, Sudarshi D, Srikrishnan AK, Celentano DD, Vasudevan CK, Anand S, et al. Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction 2012; 107:349-358.
29. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One 2012; 7:e39819.